Deakin University
Browse

File(s) not publicly available

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

journal contribution
posted on 2023-02-20, 22:16 authored by A Strezova, J Diez-Domingo, K Al Shawafi, JC Tinoco, M Shi, P Pirrotta, A Mwakingwe-Omari, M Adams, A Ahonen, C Andrews, Eugene AthanEugene Athan, JF Barbagómez, P Barbanti, E Barberan, A Baty, N Bengtsson, J Berger-Roscher, KB Blom, J Beytout, L Boucher, C Boutry, A Boye, F Brault, L Breger, CB Cuixart, C Caso, C Cerna, HS Cheng, HJ Cheong, EJ Choo, C Cunha, AL Cunningham, D Curiac, B Daguzan, A Dahmen, S Datta, MG Desole, ED Paolo, M Dionne, P Dite, J Dutz, J Earl, T Eckermann, W Ellison, J Eremenko, M Esen, T Eto, XF Fabré, C Farrington, M Ferguson, PA Ferrand, M Finneran, D Francyk, M Freedman, G Freeman, AT Freire, P Gal, JS Gauthier, B Gerlach, W Ghesquiere, I Gorfinkel, C Grigat, J Grosskopf, M Hamann, P Hanrion, P Hartley, A Hastie, K Heaton, A Himpel-Boenninghoff, T Horacek, DSC Hui, Y Huong, SJ Hwang, G Icardi, G Illies, J Irimajiri, W Jacob, A Jambrecina, TJ Avelino-Silva, G Kalema, HY Kim, C Klein, U Kleinecke, HJ Koenig, S Kokko, P Kosina, S Koski, P Koskinen, M Kropp, R Kuroki, O Laajalahti, P Lachance, J Lee, JS Lee, P Levins, R Lipetz, B Liu, CS Liu, M Lundvall, L Magimaiseelan
Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.

History

Journal

Open Forum Infectious Diseases

Volume

9

Pagination

ofac485-

Location

United States

Publisher DOI

ISSN

2328-8957

eISSN

2328-8957

Language

en

Author URL

Issue

10

Publisher

Oxford University Press (OUP)

Usage metrics

    Research Publications

    Categories

    No categories selected

    Keywords

    adjuvanted recombinant zoster vaccineimmune response persistencelong-term efficacylong-term safetyZoster-049 Study GroupImmunizationBiotechnologyPatient SafetyPreventionVaccine Related3 Prevention of disease and conditions, and promotion of well-being3.4 VaccinesInfection3 Good Health and Well Being

    Licence

    All Rights Reserved

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC